Skip to content
logo-removebg-preview (2)
  • Home
  • Our Team
    • Board of Directors
    • Management
    • Join Our Team
    • Academic Collaboration
  • Areas of Focus
    • Scientific Approach
    • Therapeutic Areas
  • Pipeline
    • Development Pipeline
    • AIV001
    • AIV007
    • JEL Technology
  • Investor
    • News
    • Press Releases
    • Events
    • Partnerships
  • Contact
New Logo
  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact

Archive for May 2023

AiViva BioPharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema  

By AiViva BioPharma | May 22, 2023

Costa Mesa, Calif., May 22, 2023 – AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of…

Read More

Recent Posts

  • AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
  • AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
  • AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
  • AiViva BioPharma Appoints Les Kaplan, PhD, to the Board of Directors
  • AiViva BioPharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors

Recent Comments

No comments to show.
New Logo

1451 Quail Street, Suite 204
Newport Beach, CA  92660

New Logo

151 Kalmus Drive, Building C, Suite C-200
Costa Mesa, CA 92626

  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact
  • Home
  • Our Team
  • Therapeutic Areas
  • Development Pipeline
  • Events
  • Partnerships
  • Contact

© 2026 AiViva BioPharma. All Rights Reserved.

GoDaddy Web Design
Scroll To Top